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Summary
 
The ability of interleukin (IL)-12 to prevent tumors when administered to individuals with a
genetic risk of cancer was studied in two lines of transgenic mice expressing rat HER-2/
 
neu
 
oncogene in the mammary gland. Female BALB/c (H-2
 
d
 
) mice carrying the activated HER-2/
 
neu
 
 oncogene show no morphological abnormalities of the mammary gland until 3 wk of age.
They then progress through atypical hyperplasia to in situ lobular carcinoma and at 33 wk of
age all 10 mammary glands display invasive carcinomas. Adult FVB mice (H-2
 
q
 
) carrying the
HER-2/
 
neu
 
 protooncogene develop mammary carcinomas with a longer latency (38-49 wk)
and a lower multiplicity (mean of 2.6 tumors/mice). Treatment with IL-12 (5 daily intraperito-
neal injections, 1 wk on, 3 wk off; the first course with 50 ng IL-12/day, the second with 100 ng
IL-12/day) begun at 2 wk of age in BALB/c mice and at 21 wk of age in FVB mice markedly
delayed tumor onset and reduced tumor multiplicity. Analogous results were obtained in im-
munocompetent and permanently CD8
 
1
 
 T lymphocyte–depleted mice. In both transgenic
lines, tumor inhibition was associated with mammary infiltration of reactive cells, production
of cytokines and inducible nitric oxide synthase, and reduction in microvessel number, in com-
bination with a high degree of hemorrhagic necrosis.
Key words: interleukin 12 • adenocarcinomas • tumor prevention • angiogenesis • Her-2/
 
neu
 
C
 
urrent genetic studies are leading to the identification
of gene mutations that predispose to cancer. They
thus hold out the hope that not-yet affected patients or
“unpatients” with a defined genetic prognosis can be de-
tected (1). This, indeed, is already a reality in breast cancer,
one of the most common malignancies in women.
With the paucity of effective preventive options, prob-
ing of the human genome is raising new and dramatic ethi-
cal, psychological, and cultural issues (1). On the other
hand, identification of a mutated gene and its altered or
amplified products is providing a new chance of undertak-
ing immunologic maneuvers against oncogene products (2)
in an unprecedented setting, where they may be able to
prevent the onset or inhibit the initial growth of tumors in
healthy individuals with a high risk of cancer.
This paper offers evidence of the efficacy of administra-
tion of mouse recombinant IL-12 (rIL-12) in counteracting
the occurrence and progression of spontaneous mammary
carcinomas in the females of two lines of inbred mice trans-
genic for the rat HER-2/
 
neu
 
 oncogene under the tran-
scriptional control of mouse mammary tumor virus
(MMTV)
 
1
 
 LTR (3). BALB–NeuT female mice are from a
new line of transgenic BALB/c mice carrying the activated
HER-2/
 
neu
 
 oncogene (4) and presenting high mammary
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tumor multiplicity and relatively fast tumor growth (5).
FVB–NeuN females carry the HER-2/
 
neu
 
 protooncogene
(6) and display lower multiplicity and longer latency. Pro-
longed administration of low doses of rIL-12 delayed tu-
mor onset and reduced tumor multiplicity in both lines.
Analogous results were obtained in BALB–NeuT mice
permanently depleted of CD8
 
1
 
 T lymphocytes.
Tumor inhibition in both lines was associated with defi-
cient peri- and intratumoral angiogenesis, infiltration of re-
active cells, production of proinflammatory cytokines, and
inducible nitric oxide synthase (iNOS) activation. Vascular
damage resulted in a high degree of hemorrhagic necrosis
of established tumor masses.
 
Materials and Methods
 
Mice.
 
A transgenic CD1 random-bred breeder male mouse
(no. 1330) carrying the mutated rat HER-2/
 
neu
 
 oncogene driven
by the MMTV promoter (Tg-NeuT, provided by Dr. L. Clerici,
Euratom, Ispra, Italy; reference 5) was mated with BALB/c fe-
males (H-2
 
d
 
; Charles River, Calco, Italy). The progeny was
screened for the transgene by PCR. Transgene-carrying males
were backcrossed with BALB/c females for 12 generations and
HER-2/
 
neu 
 
1
 
 BALB/c mice (BALB–NeuT) were used in these
experiments. Parental FVB–NeuN N#202 transgenic mice (6)
carrying the rat HER-2
 
/neu
 
 protooncogene driven by the
MMTV promoter on the H-2
 
q
 
 FVB inbred background were
provided by Dr. W.J. Muller (McMaster University, Hamilton,
Ontario, Canada) and bred in our animal facilities. Females of
both transgenic lines show a MMTV-driven overexpression of
the transgene in the mammary gland and a definite tumor growth
involving the mammary gland epithelium (5–7). Individually
tagged virgin females were used in this study. Starting at the age
of 5 wk, their mammary glands were inspected once a week, and
masses were measured with calipers in the two perpendicular di-
ameters (8). Progressively growing masses 
 
.
 
3 mm mean diameter
were regarded as tumors. BALB–NeuT mice were killed at wk
33 when these masses were evident in all 10 mammary glands.
FVB–NeuN mice were killed when a mammary mass exceeded
2 cm mean diameter, and surviving mice were killed at 61 wk.
All mice were evaluated histologically for mammary tumor devel-
opment and toxicity related to IL-12 administration.
 
IL-12 Administration.
 
rIL-12 (Genetics Institute, Cambridge,
MA) in HBSS supplemented with 0.01% mouse serum albumin
(MSA; Sigma Chemical Co., St. Louis, MO) was administered
intraperitoneally. MSA control mice received similar injections of
MSA only.
 
Depletion of CD8
 
1
 
 Lymphocytes.
 
After thymectomy, a few
BALB–NeuT neonatal mice were thymectomized and received
200 
 
m
 
g of purified anti-CD8
 
1
 
 cell mAb (53.6.72 hybridoma,
anti-Lyt2; American Type Culture Collection, Rockville, MD)
injected intraperitoneally 2 d later. Complete removal of thymus
lobes and effective CD8
 
1
 
 T lymphocyte depletion was checked
at 33 wk. Immunofluorescence of lymph node cells was per-
formed by staining with FITC-conjugated rat anti mouse CD3
(clone 145-2C11), CD4 (clone RM4-4), or CD8 (clone 53-6.72)
mAbs (all from PharMingen, San Diego, CA). Cytofluorometry
showed a persistent reduction and depletion of CD8
 
1
 
 lympho-
cytes (
 
,
 
4%) compared with untreated mice.
 
Morphologic Analysis.
 
Groups of two or three BALB–NeuT
mice were killed at wk 2 and 3 and then every other week until
wk 33; similar groups of FVB–NeuN were killed every 4 wk
from wk 5 to 61. For histologic evaluation, tissue samples were
fixed in 10% neutral-buffered formalin, embedded in paraffin,
sectioned at 4 
 
m
 
m, and stained with hematoxylin and eosin or
Giemsa. For immunohistochemistry, acetone-fixed cryostat sec-
tions were incubated for 30 min with anti-CD4, anti-CD8a (all
from Sera-Lab, Crawley Down, Sussex, UK), anti–Mac-1 (anti
CD11b/CD18), anti–Mac-3, and anti-Ia (all from Boehringer
Mannheim, Milan, Italy), antipolymorphonuclear leukocytes
(RB6-8C5; provided by Dr. R.L. Coffman, DNAX Inc., Palo
Alto, CA), antiendothelial cells (mEC-13.324; reference 9), anti–
IL-1
 
a
 
 (Genzyme Corp., Cambridge, MA), anti–TNF-
 
a
 
 (Im-
muno Kontact, Frankfurt, Germany), anti–IFN-
 
g
 
 (10), anti–IL-6
(PharMingen), and anti-iNOS (Transduction Laboratories, Lex-
ington, KY) antibodies. After washing, the cryostat sections were
overlaid with biotinylated goat anti–rat, anti–hamster, and anti–
rabbit or horse anti–goat Igs (Vector Labs., Burlingame, CA) for
30 min. Unbound Ig was removed by washing and the slides
were incubated with avidin–biotin complex (ABC)/alkaline
phosphatase (AP) (Dako, Glostrup, Denmark). Quantitative stud-
ies of immunohistochemically stained sections were performed
independently by three pathologists in a blind fashion. From mice
with multiple tumors, 2 or more samples (1/tumor growth area)
and 10 randomly chosen fields in each sample were evaluated for
each point determination. For microvessel and cell counts, indi-
vidual microvessels and cells were counted under a microscope
 
3
 
400 field (
 
3
 
40 objective and 
 
3
 
10 ocular lens; 0.180 mm
 
2
 
 per
field). The expression of adhesion molecules, cytokines, and me-
diators was defined as absent (
 
2
 
) or scarcely (
 
1
 
/
 
2
 
), moderately
(
 
1
 
), or frequently (
 
11
 
) present on cryostat sections tested with
the corresponding antibodies.
 
mRNA for Cytokine.
 
Total RNA was prepared from carci-
noma masses of mice treated or not with rIL-12 by using Ultraspec
(Biotecx Lab. Inc., Houston, TX). 2 
 
m
 
g of RNA were reverse
transcribed with Moloney murine leukemia virus reverse tran-
scriptase (200 U) in 50 
 
m
 
l of reaction mixture with oligo dT and
dNTP (GIBCO BRL, Paisley, UK). The cDNA were tested for
the presence of murine glucose 3-phosphate dehydrogenase, IL-
1
 
a
 
, IL-6, IFN-
 
g
 
, TNF-
 
a
 
, GM-CSF, monokine induced by 
 
g
 
-IFN
(MIG), and IFN-
 
g
 
–inducible protein (IP-10) sequences in PCR
reactions (Gene Amp Kit; Perkin Elmer Cetus, Norwalk, CT) per-
formed in 50 
 
m
 
l volumes, by using specific primer pairs prepared
by us (IP-10 and MIG) or from Clontech (Palo Alto, CA). The re-
sults are arbitrarily scored from 
 
2 
 
to 
 
111
 
 based on the intensity
of UV fluorescence of the ethidium bromide–stained gels as inde-
pendently evaluated by two operators in a blind fashion.
 
Figure 1.
 
Progression of HER-2
 
/neu
 
 carcinogenesis in untreated BALB–NeuT and FVB–NeuN female mice. (
 
A
 
) Successive alterations of the mam-
mary gland in untreated BALB–NeuT mice and indications of the time of 5-d courses of rIL-12 administration (
 
h
 
, 50 ng/day; 
 
j
 
, 100 ng/day). Histol-
ogy shows that ductular atypical hyperplasia (
 
a
 
) is already evident and widely distributed in all mammary glands at 3 wk of age. This hyperplasia progresses
to carcinoma in situ (
 
b
 
) between wk 13 and 17, and then to an invading lobular carcinoma (
 
c
 
). (
 
B
 
) Successive alterations of the mammary gland in FVB–
NeuN mice during the 61-wk follow-up. Squares (
 
h
 
, 
 
j
 
, as in 
 
A
 
). Histology shows that the mammary glands are normal (
 
a
 
) until at least wk 29 of age.
Thereafter the neoplastic process begins in one mammary gland with focal hyperplasia and carcinoma in situ (
 
b
 
) and progresses by giving rise to an inva-
sive lobular carcinoma (
 
c
 
) between wk 39 and 48. Original magnification: 
 
3
 
630. 
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Statistical Analysis.
 
Differences in tumor incidence were eval-
uated by the Mantel-Haenszel log-rank test, those in tumor/
mouse numbers by Wilcoxon’s rank sum test, and those in the
number of tumor infiltrating cells by Student’s 
 
t
 
 test.
 
Results
 
At week 33, lobular carcinomas were palpable in all 10
mammary glands of BALB–NeuT females carrying the ac-
tivated HER-2/
 
neu
 
 oncogene (Fig. 1 
 
A
 
). FVB–NeuN fe-
males carrying the HER-2/
 
neu
 
 protooncogene display one
or more mammary glands with tumor at 49 wk, and the
mean number affected at 61 wk is still very low (Fig. 1 
 
B
 
).
This rapid onset and total gland involvement suggests that
expression of activated HER-2/
 
neu
 
 in BALB–NeuT mice
requires few, if any, additional genetic events to transform
the mammary epithelial cell (7), whereas the delayed onset
and asynchronous progression observed in the other line
indicates that overexpression of HER-2/
 
neu
 
 protoonco-
gene results in stochastic tumor development.
These kinetic patterns provide two distinct models of
HER-2/
 
neu mammary oncogenesis with which to test the
effect of prolonged administration of low doses of rIL-12.
Since histologic examination revealed that widespread atyp-
ical hyperplasia was already evident in the mammary glands
of 3-wk-old BALB–NeuT mice, and HER-2/neu mam-
mary oncogenesis quickly progressed to overt carcinoma,
these mice first received a 5-d course of 50 ng of rIL-12
plus MSA, injected intraperitoneally at 2 wk of age. The
dose was then increased to 100 ng, and 5-d courses fol-
lowed by 3 wk off were run from wk 5 to 29 (Fig. 1 A).
MSA control mice received similar courses of MSA only.
Mice were inspected weekly. Those displaying progres-
sively growing masses in all 10 mammary glands and those
that reached 33 wk of age were killed and morphologically
examined.
A significant delay in the onset of the first mammary tu-
mor was evident in the treated mice as compared with the
MSA controls. Moreover, at wk 33 the number of mam-
mary glands with a palpable tumor was much lower (Fig. 2,
top). Histologic examination of the mammary glands at
progressive time points in a fashion blind to the treatment
revealed a general delay in the progression of the HER-2/
neu oncogenesis in the treated mice. Atypical hyperplasia
was less vigorous and less widely distributed than in the
MSA controls, and no carcinoma in situ was found before
wk 15 (data not shown). This delay in tumor progression
was associated with deficient neovascularization and a
marked increase in infiltrating CD81, and to a lesser extent
CD41, lymphocytes (Table 1). Lymphocyte infiltration was
concomitant with enhanced vascular cell adhesion mole-
cule (VCAM)-1 expression (Fig. 3), as well as expression of
mRNA for proinflammatory cytokines and their produc-
tion (Table 1). Extensive expression of iNOS on tumors
from treated mice was shown immunohistochemically (Fig.
3). This suggests that IL-12-primed NO exerted a cyto-
toxic and antitumor activity directly or through its reactive
products (11, 12). Moreover, strong expression of IP-10
and MIG mRNA was revealed by reverse transcriptase
PCR in the tumor area from treated mice (Table 1). These
two chemokines mediate the antiangiogenic activity of IL-12,
and, in combination, chemoattract activated T cells (13–
15). Their modulation is probably a consequence of IL-12–
induced expression of IFN-g and TNF-a in NK and T
cells. IFN-g and TNF-a also amplify the production of
proinflammatory cytokines, angiogenic inhibitors, and NO
by reactive cells (15). This multifactorial scenario offers an
explanation for both the inhibition of tumor neoangiogen-
esis and vascular damage leading to the impressive ischemic
and hemorrhagic necrosis of advanced carcinomas in rIL-
12–treated BALB–NeuT mice (Fig. 4).
Our previous studies have shown that CD81 lympho-
cytes play a pivotal role in the antitumor reaction elicited
by IL-12, whereas CD41 cells play an inhibitory role (8,
16, 17). To evaluate the weight of CD81 cells in rIL-12-
delayed oncogenesis, BALB–NeuT mice treated with rIL-
12 or MSA only were thymectomized at 4 wk and received
Figure 2. Inhibition of mammary carcinogenesis in HER-2/neu trans-
genic female mice treated with rIL-12. Percentage of tumor-free mice
and mean number of palpable mammary carcinomas per mouse calculated
as cumulative number of incident tumors/total number of BALB–NeuT
mice, BALB–NeuT mice CD81 T lymphocyte depleted by neonatal
thymectomy and anti-CD81 mAb treatment, and FVB–NeuN mice
treated with rIL-12 (j) or MSA only (h). Stars (w) denote time points at
which tumor multiplicity was significantly different (P ,0.05 at least) be-
tween MSA and rIL-12 treatment groups. Group sizes were: BALB–
NeuT: 38 MSA control mice and 43 rIL-12–treated mice; thymecto-
mized and anti-CD81 mAb treated BALB–NeuT mice: 10 MSA control
mice, 6 rIL-12–treated mice; FVB–NeuN: 8 mice each group.593 Boggio et al.
200 mg of anti-CD8 mAb intraperitoneally. Both the pro-
gression of mammary oncogenesis and the protective effect
of IL-12 were unaffected by this permanent CD81 deple-
tion (Fig. 2, middle).
The protective effect of rIL-12 was also evident in FVB–
NeuN mice. Here, because of the slower tumor progres-
sion and the virtual absence of atypical mammary hyperplasia
foci before wk 29, the initial 5-d course was administered
to 21-wk-old mice (Fig. 1 B), followed the by same sched-
ule as for the BALB–NeuT mice until wk 57. Mice dis-
playing a tumor mass .2 cm mean diameter and those that
reached the wk 61 of age were killed: 50% of the treated
mice were tumor-free, whereas all of the MSA controls
displayed palpable tumors. The mean number of mammary
glands with a palpable tumor was 2.6 per mouse in the
MSA controls compared with only 0.9 in the IL-12–treated
mice (Fig. 2, bottom). Deficient peri- and intratumoral vas-
cularization, enhanced expression of adhesion molecules,
enhanced CD81 infiltration, cytokine production, and iNOS
activation (Table 1 and Fig. 5), and large areas of hemor-
rhagic necrosis in established tumors (Fig. 4) were evident,
as in the IL-12–treated BALB–NeuT mice.
Increased spleen and liver extramedullary hematopoiesis
and a slight exacerbation of hepatic periportal mononuclear
Table 1. Effects of rIL-12 Treatment on Neovascularization, the Expression of Adhesion Molecules, the Secretion of Mediators, and the 
Infiltration by Reactive Cells in 7-mm Mean Diameter Tumors Growing in BALB–NeuT and FVB–NeuN Female Mice
BALB–NeuT mice FVB–NeuN mice
MSA MSA 1 IL-12 MSA MSA 1 IL-12
Pathologic findings (immunohistochemistry)
Microvessel count 15.9 6 2.1 9.5 6 1.3* 19.7 6 3.7 10.5 6 2.4*
Endothelial adhesion molecules
ICAM-1 1111
VCAM-1 21 121 1
ELAM-1 21 / 22 2
Infiltrating cells
Macrophages 12.5 6 4.1 13.4 6 3.8 16.1 6 4.2 14.2 6 5.2
Granulocytes 5.2 6 1.9 7.6 6 2.3 5.0 6 2.8 6.9 6 3.0
CD81 lymphocytes 2.9 6 0.8 42.0 6 8.3* 4.8 6 2.1 14.6 6 6.1*
CD41 lymphocytes 3.1 6 1.7 15.2 6 5.1* 3.6 6 1.9 5.7 6 2.6
Cytokines and mediators
IL-1b2 1 / 221 / 2
TNF-a1 / 211 / 21
IFN-g 2121
IL-6 1/211 / 21
iNOS 21 121 1
Reverse transcriptase PCR (mRNA)
Cytokines and chemokines
IL-1b 11 111 NT‡ NT
TNF-a2 1 NT NT
IFN-g2 1 / 2 NT NT
IL-6 11 11 NT NT
GM-CSF 1/21 NT NT
MIG 11 1 NT NT
IP-10 11 1 NT NT
Microvessel counts were performed on cryostat sections tested with an antiendothelial (CD31) mAb as described in Materials and Methods. The ex-
pression of adhesion molecules, cytokines, and mediators on cryostat sections was probed with the corresponding mAb. From mice with multiple tu-
mors, two or more samples (one sample per tumor) were evaluated. At least 10 fields were counted per sample. Values are expressed as mean 6 SD
of five Balb–NeuT and four FVB–NeuN mice. An arbitrary score (from 2 to 111) was used to indicate the amount of detected signal in a semi-
quantitative reverse transcriptase PCR analysis, as described in Materials and Methods. At least three independent tumors from Balb–NeuT mice
were evaluated, and a representative expression pattern is shown.
*Value significantly different (P ,0.001) than that in MSA-treated mice.
‡NT, not tested.594 Interleukin 12 Prevents Spontaneous Mammary Adenocarcinomas
infiltration were the only signs of chronic rIL-12–related
lesions in both lines of mice, showing that this cytokine is
effective at well-tolerated doses.
Discussion
rIL-12 administration in young BALB–NeuT mice car-
rying the activated Her-2/neu oncogene delays the appear-
ance of tumor and reduces the number of mammary glands
involved. In adult FVB–NeuN mice carrying the HER-2/
neu protooncogene, neoplastic progression is less impetuous
and 50% of IL-12–treated mice are tumor-free at 1 yr.
Since pathologic examinations suggest that rIL-12 does not
lead to an appreciable failure in normal mammary tissue de-
velopment, the increased percentage of FVB–NeuN–pro-
tected mice may mean that progression was delayed by rIL-
12 beyond the 61 wk of the experiment.
The protection offered by rIL-12 could, of course, be as-
cribable to its triggered killing of neoplastic cells, thus off-
setting the continuous generation of new transformed cells
by the transgenic mammary tissue. However, in contrast
with the rIL-12–induced immune reaction against estab-
lished carcinomas (8), the results obtained with thymecto-
Figure 3. Cryostat sections of invading lobular carcinomas in MSA
control (a and c) and IL-12–treated (b and d) BALB–NeuT mice. VCAM-1
is absent in tumor blood vessels of MSA control mice (a), whereas it is ex-
pressed in those of rIL-12–treated mice (b) as revealed by anti–VCAM-1
mAb. In the MSA control tumors, iNOS expression is almost undetect-
able in macrophages (c), whereas in rIL-12–treated mice it is clearly evi-
dent in macrophages intermingled among tumor cells (d) as shown by
anti-iNOS mAb. Observations made in 7-mm mean diameter tumors.
Similar patterns are evident in all established tumors. Original magnifica-
tion: 3630.
Figure 5. Cryostat sections of invading lobular carcinomas in MSA
control (a and c) and IL-12–treated (b and d) FVB–NeuN mice. TNF-a
(b) and IFN-g (d) are evident in the tumor growth area in IL-12–treated
mice, whereas both are absent (a and c) in the MSA control, as revealed by
staining with anti–TNF-a and –IFN-g mAb in tumor masses of 49-
wk-old mice. Original magnification: 3630.
Figure 4. Histologic features of invading lobular carcinomas in BALB–NeuT (a) and FVB–NeuN (d) MSA control mice and in rIL-12–treated BALB–
NeuT (b and c) and FVB–NeuN (e and f) mice. The impressive ischemic and hemorrhagic necrosis disaggregating the neoplastic masses becomes evident
from wk 27 in BALB–NeuT (b) and wk 53 in FVB–NeuN (e) mice. In both cases it eventually results in extensive tumor destruction (c and f). Original
magnification: 3630.595 Boggio et al.
mized BALB–NeuT mice suggest that CD81 lymphocytes
do not play a major role here, even if they are the domi-
nant population of reactive cells infiltrating the tumor area
in rIL-12–treated mice. It is possible that NK cells are the
leading actors in this IL-12–provoked delay in oncogenesis
(18). Since the NK1.1 mAb recognizes an allelic form of an
NK cell antigen expressed by C57BL/6 but not BALB/c
mice, the type and function of lymphocytes first involved
are currently under investigation in (BALB/c 3 C57BL/6)
NeuT1 F1 mice.
The nonessential role of cytotoxic CD81 lymphocytes in
vivo fits in well with both the marginal cytotoxic activity
and the lymphokine release observed when T lymphocytes
from rIL-12–treated mice were restimulated in vitro with
APCs pulsed with the product of the rat HER-2/neu onco-
gene (p185), a self-protein in these transgenic mice (data
not shown). These findings, along with morphologic data,
rather suggest that rIL-12 essentially protects by halting an-
giogenesis (19) through the induction of several secondary
cytokines and mediators, thus slowing down the transition
from hyperplasia to overt carcinoma (20, 21). Moreover,
the secondary cytokines and the tertiary chemokines and
monokines elicited by IL-12 are apparently responsible for
later vessel endothelial wall injury and hemorrhagic necro-
sis of established tumors (12, 13, 22–24). The endothelial
vessel alteration and hemorrhagic necrosis observed in both
lines of rIL-12–treated mice are reminiscent of those ob-
served during rejection of an established transplantable
mammary adenocarcinoma in BALB/c mice treated with
systemic rIL-12 or adenocarcinoma cells engineered to re-
lease IL-12 (8).
Whether immunological maneuvers in healthy individu-
als at risk prevent the development of cancer is a question
that has rarely been examined. Most studies have evaluated
immunization before transplantation with frank tumor
cells. Immunoprevention of cancer has been attempted in a
few models of chemical carcinogenesis. Interpretation of
these experiments may be confounded by the fact that car-
cinogens may be immunosuppressive.
Noguchi et al. have shown that similar doses of IL-12 in-
hibit 3-methylcholanthrene carcinogenesis in mice through
the release of cytokines and mediators and nonspecific im-
mune mechanisms (25). Our findings extend these observa-
tions by underscoring the potential of nonspecific immune
mechanisms and their cross-talk with the endothelial cells
of tumor vessels in the inhibition of HER-2/neu oncogen-
esis.
The HER-2/neu oncogene is expressed in a substantial
proportion of human mammary carcinomas and its product
seems to be a promising target for specific immune inter-
vention (26). However, its expression in humans is not the
same as the expression of a xenogenic oncogene in trans-
genic mice, and this issue may somewhat impact specific
immunization rather than nonspecific immune mecha-
nisms. The close resemblance of the progression of mam-
mary carcinogenesis in HER-2/neu transgenic mice to that
in women suggests that chronic administration of nontoxic
rIL-12 regimens may be a significant prophylactic strategy.
The direct proportionality between the length of carcino-
genesis progression and the efficacy of rIL-12 suggest that a
“soft” immunologic alternative to controversial and dis-
tasteful mastectomy may be envisaged.
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